To evaluate the potential for CD21 CAR-T in a dual-targeting approach, we used flow cytometry to compare CD21 expression with the previously described T-ALL targets CD7, CCR9, and CD1a in 50 of these already described diagnostic T-ALL samples, where extended phenotyping was available. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.